Navigation Links
VCU study shows hormone-like molecule kills cells that cause inflammation in allergic disease

Virginia Commonwealth University immunologists studying mast cells, known to play a central role in asthma and allergic disease, have identified a hormone-like molecule that can kill these cells by programming them to die in studies with mice.

The findings move researchers another step closer to understanding the life cycle of mast cells, and may help researchers develop new treatments for allergy and inflammatory responses in arthritis, multiple sclerosis and heart disease.

In the Journal of Immunology, published online Aug. 23, researchers demonstrated the means by which a cytokine called interferon gamma (IFNγ induces death of developing mast cells in a mouse model system. Although IFNγ induced cell death in developing mast cells, it did not affect the survival of mast cells that had already undergone differentiation.

"We believe that cytokines, such as interferon gamma, are an important means of controlling mast cell function in the body," said John J. Ryan, Ph.D., associate professor of biology at VCU and lead author of the study. "Because mast cells cause inflammation, regulating how many mast cells the body makes, where they go, what they do, and when they die can have a huge impact on health and disease.

"For example, there has been one report of a patient with mastocytosis, which is a type of pre-leukemia where mast cells proliferate abnormally, that showed improvement with IFNγ treatment," he said. "It is possible that other mast cell-related diseases, such as asthma, may respond to IFNγ treatment."

According to Ryan, mast cells are packed with granules containing histamine and are present in nearly all tissues except blood. When mast cells are activated, inflammatory substances such as histamine, heparin and a number of cytokines are rapidly released into the tissues and blood, promoting an allergic reaction.

Mast cells are believed to be generated by different precursor cells in the bone marrow.

In the in vitro portion of the study, researchers used mouse bone marrow cells containing the stem cells that give rise to mast cells. They cultured these precursor cells in conditions that allow mast cells to develop, and then added IFNγ to some of these cultures. A high rate of cell death yielding no living mast cells was observed in the cultures that received IFNγ.

Similar results were reported in vivo using a mouse model. Mice with a mutation that causes them to overproduce IFNγ were used, and again, researchers observed a significant decrease in mast cell numbers due to the excess of IFNγ. When researchers tried to culture mast cells from the bone marrow of these mice, the mast cells died.

Furthermore, a separate strain of mice with the same mutation as the first strain, but that had also been engineered to prevent IFNγ production, were found to have almost as many mast cells as normal mice, if not more. They concluded that the presence of high IFNγ levels blocked mast cell development.


Source:Virginia Commonwealth University

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:

(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
Breaking Biology Technology: